Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions

Pancreatic CancerNeoadjuvant Therapy

Interventions

DRUG

Adebrelimab

1200mg，i.v. , q3w

DRUG

albumin-bound paclitaxel

125 mg/m2, i.v.,d1,d8, q3w

DRUG

Gemcitabine

1.0 g/m2, i.v.,d1, d8, q3w

Trial Locations (1)

RECRUITING

Wang Sizhen, Nanjing

All Listed Sponsors

collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Jinling Hospital, China

OTHER